Drug developed at Ohio State shows promise in treating COVID-19 patients at high-risk for Acute Respiratory Distress Syndrome
Oncology biopharmaceutical company Veru announced positive efficacy and safety results from a Phase 2 clinical trial VERU-111 versus placebo in approximately 40 hospitalized patients at high risk for Acute Respiratory Distress Syndrome (ARDS) from SARS-CoV-2. The drug, originally developed as a treatment for prostate cancer, was partially developed at The Ohio State University.
Oncology biopharmaceutical company Veru announced positive efficacy and safety results from a Phase 2 clinical trial VERU-111 versus placebo in approximately 40 hospitalized patients at high risk for Acute Respiratory Distress Syndrome (ARDS) from SARS-CoV-2. The drug, originally developed as a treatment for prostate cancer, was partially developed at The Ohio State University.